BerGenBio

Selective AXL inhibitors

Home  /  Investors

Investors

Yearly Reports

Annual Report 2020

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Corporate Presentation

SACHS 7th Annual Immuno-Oncology Innovation Forum 2021

18 May 2021

Read More

Share price

BerGenBio ASA

BGBIO (Norway: Oslo)

At close: 4:25PM CEST
-0 (-nan%)
Share Price Chart

News

Latest News

BERGENBIO ASA: RESULTS FOR THE THIRD QUARTER OF 2021

BERGENBIO PRESENTS PRE-CLINICAL AND CLINICAL data on BEMCENTINIB IN STK11-POSITIVE NSCLC at SITC Annual Meeting 2021

BERGENBIO RECEIVES FDA FAST TRACK DESIGNATION FOR BEMCENTINIB in STK11-mutated advanced/metastatic Non-small cell lung cancer (NSCLC)

More News

Scientific Presentations

SITC 2021, Rolf A. Brekken et al.

9th November 2021

Read More

Annual Report 2020

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Events

Upcoming Events

BERGENBIO ASA: Invitation to THIRD quarter 2021 results

BERGENBIO ASA: Invitation to PRESENTATION OF SECOND quarter and HALF YEAR 2021 results

BERGENBIO TO PRESENT AT ABGSC SEMINAR

BERGENBIO PRESENTING AT SACHS 7TH ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM

BERGENBIO ASA: Webcast presentation

More Events

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.